

**Company report** 

## TOP GLOVE CORP

(TOPG MK EQUITY, TPGC.KL)

16 Jan 2023

No demand lift from China despite Covid outbreak

**SELL** 

(Maintained)

## **AmInvestment Bank**

Team Coverage

Rationale for report: Company update

## **Investment Highlights**

- We maintain our SELL call on Top Glove Corporation (Top Glove) with an unchanged fair value (FV) of RM0.60/share. This is pegged to a target FY24F PE of 20x, at parity to its 10-year average. There is no ESG-related FV adjustment based on our unchanged 3-star rating.
- Following a recent meeting with management, we increased FY23F loss by 2.6x to RM349.6mil due to lower plant utilisation (PU) assumptions given the lower-than-expected PU in Dec 2022 and Jan 2023. However, we maintain FY24F-25F earnings on expectations that demand could improve by the middle of 2023.
- These are the salient highlights from the meeting:
  - Demand for Malaysian medical rubber gloves from China has not increased despite the recent spike in Covid cases in the country, mainly due to China's local supply being more than enough to cater to its domestic demand.
  - ➤ PU remained sluggish in Dec 2022 and Jan 2023 at 25%, similar to 1QFY23. This is lower than 40% guided in the most recent analyst briefing. Hence, we believe the losses in the upcoming 2QFY23 results will be similar to 1QFY23.
  - Top Glove maintained its guidance that customers could start replenishing stockpiles in 2QCY23, which is consistent with similar guidance from Hartalega Holdings.
  - According to The Edge, HARPS Holdings acquired Semperit AG Holding's medical rubber glove manufacturing segment for EUR115mil. Notwithstanding the group's current low PU and strong net cash position RM359mil as at 30 Nov 2022, management affirmed no intention of engaging in any mergerand-acquisition (M&A) activities to resolve the current oversupply scenario.
  - ➤ To recap, the medical rubber glove industry experienced oversupply in the aftermath of the H1N1 pandemic, especially in 2011. Although there were slight M&A consolidation activities back then, the oversupply was resolved by the liquidation of minor players. We note that Top Glove did not acquire smaller players until 2014.
  - By Dec 2025, Top Glove retains its target capacity of 115bil pcs/annum from 100bil pcs/annum currently, while aiming to decommission 2 old and inefficient factories (5% of its current capacity). We view the decommissioning plans positively since this will lower the cost of production and slightly improve the supply-demand dynamics in the industry.
- The stock currently trades at a FY24F PE of 27x, which is 35% above its 10-year average of 20x. We believe this is unjustified given the unabated challenges of an oversupplied sector globally, which could translate to persistent losses over the next 2 quarters.

# 03-2036 2280

 Price
 RM0.83

 Fair Value
 RM0.60

 52-week High/Low
 RM2.47/RM0.57

**Key Changes** 

Fair value EPS

YE to Aug	FY22	FY23F	FY24F	FY25F
Revenue (RM mil)	5,572.5	4,089.0	7,644.1	9,623.2
Core net profit (RM mil)	408.0	(349.6)	245.2	313.2
FD Core EPS (sen)	5.1	(4.4)	3.1	3.9
FD Core EPS growth (%)	(94.7)	(185.7)	170.1	27.7
Consensus Net Profit (RM mil)	-	-180.7	177.0	293.6
DPS (sen)	1.2	-	2.0	2.0
PE (x)	16.2	nm	26.9	21.1
EV/EBITDA (x)	7.5	nm	8.8	7.5
Div yield (%)	1.5	-	2.4	2.4
ROE (%)	4.1	(6.5)	4.6	5.8
Net Gearing (%)	nm	nm	nm	nm

#### Stock and Financial Data

Shares Outstanding (million)	8,007.3
Market Cap (RMmil)	6,606.0
Book Value (RM/share)	0.70
P/BV (x)	1.2
ROE (%)	4.1
Net Gearing (%)	nm

Major Shareholders


Tan Sri Dr Lim Wee Chai (34.7%)

EPF (4.9%)

OCBC Ltd (2.8%)

Free Float 44.2 Avg Daily Value (RMmil) 60.5

Price performance	3mth	6mth	12mth	
Absolute (%)	19.6	(19.1)	(64.7)	
Relative (%)	10.6	(23.3)	(63.3)	




Top Glove Corp 16 Jan 2023

## **EXHIBIT 1: PB BAND CHART**



## **EXHIBIT 2: PE BAND CHART**



## **EXHIBIT 3: ESG MATRIX**

Overall	*	*	*	
Biological preservation	*	*		
Water + energy conservation	*	*		
Pollution + waste regulation	*	*		
Sustainable sourcing	*	*	*	
Occupational safety + health	*	*	*	
Workplace diversity	*	*	*	
Employee training + wellbeing	*	*	*	
Volunteering + charitable giving	*	*	*	
Corruption-free pledge	*	*	*	
Accessibility & transparency	*	*	*	

We accord a discount/premium of -6%, -3%, 0%, +3% and +6% on fundamental fair value based on the overall ESG rating as appraised by us, from 1-star to 5-stars

Source: AmInvestment Bank

Top Glove Corp 16 Jan 2023

EXHIBIT 4: FINANCIAL DATA					
Income Statement (RMmil, YE 31 Aug)	FY21	FY22	FY23F	FY24F	FY25F
Revenue	16,361.4	5,572.5	4,089.0	7,644.1	9,623.2
EBITDA	10,276.4	869.9	(44.3)	745.6	873.4
Depreciation/Amortisation	(308.7)	(348.2)	(353.5)	(384.1)	(424.9)
Operating income (EBIT)	9,967.8	521.7	(397.8)	361.5	448.5
Other income & associates	2.6	(3.7)	(3.7)	(3.7)	(3.7)
Net interest	57.4	19.5	19.4	19.3	Ì9.1
Exceptional items	6.0	(172.0)	-	-	-
Pretax profit	10,033.8	365.5	(382.1)	377.1	463.9
Taxation	(2,209.8)	(73.2)	76.4	(75.4)	(92.8)
Minorities/pref dividends	(62.3)	(6.1)	6.3	(6.3)	(7.7)
Net profit	7,710.3	236.0	(349.6)	245.2	313.2
Core net profit	7,704.3	408.0	(349.6)	245.2	313.2
Balance Sheet (RMmil, YE 31 Aug)	FY21	FY22	FY23F	FY24F	FY25F
Fixed assets	4,169.4	4,709.1	4,260.2	4,487.6	4,832.5
Intangible assets	1,008.8	1,005.3	1,005.3	1,005.3	1,005.3
Other long-term assets	258.5	259.5	259.5	259.5	259.5
Total non-current assets	5,436.7	5,973.9	5,525.0	5,752.4	6,097.3
Cash & equivalent	878.4	444.1	457.4	471.1	485.3
Stock	1,144.7	564.0	667.8	1,083.6	1,368.3
Trade debtors	566.3	236.1	431.6	737.4	876.6
Other current assets	1,756.3	847.2	661.6	181.6	(164.3)
Total current assets	4,345.8	2,091.4	2,218.4	2,473.8	2,565.9
Trade creditors	692.4	426.4	548.0	877.7	1,106.2
Short-term borrowings	312.7	306.1	324.5	344.0	364.6
Other current liabilities	1,193.4	209.3	93.9	139.1	170.6
Total current liabilities	2,198.5	941.8	966.3	1,360.8	1,641.3
Long-term borrowings	146.0	93.0	95.8	98.6	101.6
Other long-term liabilities	217.8	225.9	226.4	226.8	227.3
Total long-term liabilities	363.8	318.9	322.1	325.4	328.9
Shareholders' funds	5,872.4	5,590.3	5,240.7	5,325.7	5,478.8
Minority interests	1,295.3	1,175.7	1,175.7	1,175.7	1,175.7
BV/share (RM)	0.73	0.70	0.65	0.67	0.68
Cash Flow (RMmil, YE 31 Aug)	FY21	FY22	FY23F	FY24F	FY25F
Pretax profit	10,033.8	365.5	(382.1)	377.1	463.9
Depreciation/Amortisation	308.7	348.2	353.5	384.1	424.9
Net change in working capital	(324.9)	573.0	(107.7)	133.2	181.8
Others	(2,190.7)	(1,151.1)	`458.0	(117.5)	(135.9)
Cash flow from operations	7,826.9	135.5	321.6	776.8	934.7
Capital expenditure	(1,348.6)	(918.9)	(327.1)	(611.5)	(769.9)
Net investments & sale of fixed assets	100.7	1 000 7	- 2 F	-	-
Others	100.7	1,090.7	2.5	- (/44 F)	(7(0.0)
Cash flow from investing	(1,247.9)	171.8	(324.6)	(611.5)	(769.9)
Debt raised/(repaid)	27.1	(18.9)	7.8	8.6	9.5
Equity raised/(repaid)	- (5 507 ()	(5.47.0)	-	- (4 ( 0 4 )	- (4 ( 0 4 )
Dividends paid	(5,507.6)	(547.3)	-	(160.1)	(160.1)
Others	(1,422.5)	(174.1)		-	-
Cash flow from financing	(6,903.0)	(740.3)	7.8	(151.5)	(150.7)
Net cash flow	(323.9)	(433.0)	4.8	13.7	14.1
Net cash/(debt) b/f Net cash/(debt) c/f	1,209.5 885.6	885.6 452.6	452.6 457.4	457.4 471.1	471.1 485.3
Key Ratios (YE 31 Aug)	FY21	FY22	FY23F	FY24F	FY25F
Revenue growth (%)	126.1	(65.9)	(26.6)	86.9	25.9
EBITDA growth (%)	324.1	(91.5)	(105.1)	1,782.0	17.1
Pretax margin (%)	61.3	6.6	(9.3)	4.9	4.8
Net profit margin (%)	47.1	4.2	(8.6)	3.2	3.3
Interest cover (x)	nm	nm	nm	nm	nm
Effective tax rate (%)	22.0	20.0	20.0	20.0	20.0
Dividend payout (%)	67.6	40.7		65.3	51.1
Debtors turnover (days)	13	40.7	nm 39	05.3 35	33
Stock turnover (days)	13 79	40 56	58	59	59
	79 48	36 48		59 48	
Creditors turnover (days)	48	4δ	48	48	48

Source: Company, AmInvestment Bank Bhd estimates

Top Glove Corp 16 Jan 2023

#### **DISCLOSURE AND DISCLAIMER**

This report is prepared for information purposes only and it is issued by AmInvestment Bank Berhad ("AmInvestment") without regard to your individual financial circumstances and objectives. Nothing in this report shall constitute an offer to sell, warranty, representation, recommendation, legal, accounting or tax advice, solicitation or expression of views to influence any one to buy or sell any real estate, securities, stocks, foreign exchange, futures or investment products. AmInvestment recommends that you evaluate a particular investment or strategy based on your individual circumstances and objectives and/or seek financial, legal or other advice on the appropriateness of the particular investment or strategy.

The information in this report was obtained or derived from sources that AmInvestment believes are reliable and correct at the time of issue. While all reasonable care has been taken to ensure that the stated facts are accurate and views are fair and reasonable, AmInvestment has not independently verified the information and does not warrant or represent that they are accurate, adequate, complete or up-to-date and they should not be relied upon as such. All information included in this report constituteAmInvestment's views as of this date and are subject to change without notice. Notwithstanding that, AmInvestment has no obligation to update its opinion or information in this report. Facts and views presented in this report may not reflect the views of or information known to other business units of AmInvestment's affiliates and/or related corporations (collectively, "AmBank Group").

This report is prepared for the clients of AmBank Group and it cannot be altered, copied, reproduced, distributed or republished for any purpose without AmInvestment's prior written consent. AmInvestment, AmBank Group and its respective directors, officers, employees and agents ("Relevant Person") accept no liability whatsoever for any direct, indirect or consequential losses, loss of profits and/or damages arising from the use or reliance of this report and/or further communications given in relation to this report. Any such responsibility is hereby expressly disclaimed.

AmInvestment is not acting as your advisor and does not owe you any fiduciary duties in connection with this report. The Relevant Person may provide services to any company and affiliates of such companies in or related to the securities or products and/or may trade or otherwise effect transactions for their own account or the accounts of their customers which may give rise to real or potential conflicts of interest.

This report is not directed to or intended for distribution or publication outside Malaysia. If you are outside Malaysia, you should have regard to the laws of the jurisdiction in which you are located.

If any provision of this disclosure and disclaimer is held to be invalid in whole or in part, such provision will be deemed not to form part of this disclosure and disclaimer. The validity and enforceability of the remainder of this disclosure and disclaimer will not be affected.